Analysts Issue Forecasts for LSTA Q1 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Lisata Therapeutics in a report released on Wednesday, October 30th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings per share of ($0.74) for the quarter. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.97) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.75) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Wednesday, September 18th.

Lisata Therapeutics Stock Up 11.7 %

NASDAQ:LSTA opened at $3.16 on Thursday. Lisata Therapeutics has a 52 week low of $2.05 and a 52 week high of $3.83. The stock has a market capitalization of $26.29 million, a PE ratio of -1.23 and a beta of 1.21. The stock’s 50-day moving average price is $2.96 and its 200-day moving average price is $3.08.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.14. During the same period last year, the company earned ($0.50) EPS.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.